NHS Mounjaro warning as most will not be able to access new weight loss drug
The National Institute for Health and Care Excellence (Nice) has announced that more than 90% of eligible patients in England will not be able to access the new weight loss drug, Mounjaro, initially on the NHS. This decision comes as officials opt to prioritize individuals with the highest needs to safeguard other critical NHS services. Nice has endorsed Mounjaro, also known as tirzepatide and produced by Eli Lilly, for those with a body mass index (BMI) over 35 and at least one weight-related health issue, estimated to include approximately 3.4 million people.
To manage demand effectively, Nice has specified that around 220,000 individuals could benefit from the drug over the first three years. Following this initial period, Nice will reassess the situation and provide further guidance on the drug’s wider rollout. Mounjaro, classified as a glucagon-like peptide-1 (GLP-1) agonist, is designed to help regulate blood sugar levels. It was approved for NHS use to tackle obesity in June. The drug, administered via a once-weekly injection, is to be complemented with a reduced-calorie diet and exercise to aid weight loss.
In addition to Mounjaro, other GLP-1 agonists like semaglutide are also available in various brand names such as Wegovy, Ozempic, and Rybelsus. Professor Jonathan Benger, the chief medical officer at Nice, emphasized the importance of the decision to review the drug’s delivery process in three years due to the ever-evolving healthcare landscape.
The latest Health Survey for England indicates that 64% of adults were overweight or obese in 2022. Dr. Kath McCullough, NHS England’s national specialty advisor for obesity, highlighted the significance of integrating weight loss drugs like tirzepatide into comprehensive weight loss programs that focus on lifestyle changes. These drugs should be prioritized for those with the highest clinical need to ensure effective and safe treatment.
The phased rollout plan for Mounjaro, as outlined by Nice, includes an initial focus on patients attending specialist weight management services, equating to around 220,000 individuals. They are expected to gain access to the drug within 90 days of the guidance release on December 23. NHS England will formulate a strategy to extend access to Mounjaro to additional patient groups over the next three years, following Nice’s recommendations.
The NHS’s cautious approach in managing the rollout of tirzepatide reflects its commitment to ensuring equitable access while preserving the integrity of other healthcare services. The aim is to provide a comprehensive and effective delivery of Mounjaro to all eligible individuals over time. Weight loss drugs like tirzepatide are recognized as valuable tools in combating obesity and reducing the risk of associated health conditions. However, their effectiveness is maximized when accompanied by lifestyle changes and targeted at those with the greatest clinical need.
In summary, the NHS faces the challenge of limited initial access to the new weight loss drug, Mounjaro, due to prioritization of high-need patients. While this decision aims to protect essential services and ensure a safe rollout, it underscores the ongoing struggle against obesity within the healthcare system. Prioritizing the most vulnerable individuals for treatment reflects a strategic approach to managing healthcare resources effectively.